Recent News News

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer?

(July 25, 2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion... Continue Reading


Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

(July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a... Continue Reading


FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

(July 23, 2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor... Continue Reading


Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

(July 19, 2018)

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About... Continue Reading


FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

(July 17, 2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population... Continue Reading


Cyramza Improves Survival in Poor-Prognosis Liver Cancer

(July 12, 2018)

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab)... Continue Reading


Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

(July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely... Continue Reading


Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

(July 9, 2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to... Continue Reading


Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors

(July 6, 2018)

A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The... Continue Reading


Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma

(July 3, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell... Continue Reading


« Previous PageNext Page »